The VIII annual international partnering-forum “Life Sciences Invest. Partnering Russia” started in St. Petersburg. The first day of the Forum brought together nearly 650 people.
The key discussion topics are: ‘Pharma-2030’ strategy developed by the Russian government, pharmaceutical industry innovations, export potential development, medical preparations, transition towards the integrated market of pharmaceutical products circulation within the EAEU.
Traditionally business program began with press breakfast “The pharmaceutical industry of the future” with leading experts of the pharmaceutical field of Russia and the EAEU countries. One of the main points articulated during the press-breakfast was: the state regulation does have a direct influence over the industry investment inflow and export potential.
Mr. Vladislav Shestakov, Director of the State Institute of Drugs and Good Practices of the Ministry of Industry and Trade of the Russian Federation, stated:
“Speaking of developing the export capacity in regards to inspecting and GMP, the one thing important here is assuring Russian pharmaceutical manufacturers of success during inspections conducted by foreign regulatory authorities. In turn, it is one of the conditions necessary for launching Russian pharmaceuticals on foreign markets, which requires having a clear picture and understanding of respective requirements, and at the same time it requires aspiration for achieving recognition from the foreign regulators for the results of our internal inspections in Russia.”
The discussion over framing the integrated market proceeded later during the discussion session named “The transition to the EAEU common market of pharmaceutical circulation” and moderated by Mr. Shestakov.
A number of agreements and memorandums was signed during the discussion session. The Russian nonprofit organization “Pharmaceutical and Biomedical Clusters Union” signed two memorandums. One of them was signed by an association of legal entities as “The Republic of Kazakhstan Association for the Pharmaceutical Industry Support and Development” as an effort to strengthen coordination between the non-government organizations of the Russian Federation and the Republic of Kazakhstan within the framework of the EAEU. The other one was the Memorandum of Mutual Understanding and Support signed by the “Emil Gabrielyan Scientific Center of Drug and Medical Technology Expertise” CJSC under the Ministry of Healthcare of the Republic of Armenia. It was signed in the context of the EAEU member countries pharmaceutical markets development and designed to contribute to the public drug supply and to consolidating science, education and manufacturing industry in the field of pharmaceutical products and medical devices circulation.
The issues of the EAEU countries joining the PIC/S were also discussed. For instance, the Russian Federation pre-applied for joining the organization in 2017; the Republic of Belarus successfully finalized the pre-application procedure in 2016; the republic of Kazakhstan has been in the pre-assession process since 2013. The Republic of Armenia succeeded the pre-application in 2012 and applied for membership in the organization in 2017.
Following the results of the session, the participating parties decided to proceed with the work aimed at achieving membership in the PIC/S for the EAEU member countries, and further cooperation on framing the common market of pharmaceutical circulation within the EAEU.